Cartesian Therapeutics
NEWS
Cartesian Therapeutics’ mRNA CAR-T therapy met its primary endpoint in a mid-stage trial for the chronic autoimmune disorder and expects to raise $130 million via private placement equity financing.
After forging a partnership last year, Astellas is ending the pact with Cartesian Therapeutics and stopping the development of a Pompe disease candidate.
Boehringer Ingelheim will launch three Phase III studies for its obesity drug candidate; third time is a charm for Ipsen as it gets FDA approval; and Pfizer takes multiple myeloma battle to J&J.
The company disclosed Thursday in a second-quarter report that it will continue advancing its chronic refractory gout treatment but is suspending further investments in its pipeline.
Selecta Biosciences is moving forward with development efforts for its gene therapy program for methylmalonic acidemia after the FDA lifted the hold on its clinical trial on March 9.
Long-term, opportunities may include using the platform as a vehicle for combination therapies from assets developed by multiple companies.
Heading out of November and into December, plenty of companies had clinical trial news to report. Here’s a look.
It was another busy week for clinical trial news. Here’s a look.
Redosing is a large and growing concern for gene therapy developers and regulators.
JOBS
IN THE PRESS